Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with small cell lung cancer that has come back or stopped responding to treatment, confirmed through a laboratory test on a tissue or cell sample.
- People who have already received at least one chemotherapy treatment that included a platinum-based drug, as approved in their country and following their hospital's guidelines.
- In countries where the standard first-line treatment includes platinum chemotherapy combined with an anti-PD-(L)1 therapy (a type of immunotherapy), people whose cancer has grown despite that treatment, or for whom that immunotherapy was not an option or was not available to them.
Who may not be able to join:
- People who have cancer that has spread to the brain or spinal cord and has not yet been treated.
- People who have an active autoimmune disease, or a condition that is known or suspected to involve the immune system attacking the body.
- People who have previously received an organ or tissue transplant from another person.
- There are additional criteria set out in the study protocol that may also affect eligibility (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants with adverse events (AEs); Number of participants with serious adverse events (SAEs); Number of participants with AEs meeting dose-limiting toxicity (DLT) criteria; Number of participants with AEs leading to discontinuation; Number of participants with AEs leading to death
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.